TABLE 3.
Subgroup analysis of studies based on different NAA testsa
| Reference standard | Subgroup | Subgroup by method | No. of data sets | % sensitivity (95% CI) | % specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Culture | In-house | Conventional PCR (IS6110 gene) | 18 | 87 (77–93) | 98 (94–99) | 39.5 (15.7–77.1) | 0.13 (0.07–0.25) | 307 (106–888) | 98 (96–99) |
| Conventional PCR (MPB64 gene) | 4 | 92 (81–97) | 98 (78–99) | 52.0 (3.4–778.4) | 0.08 (0.03–0.20) | 275 (42–1,814) | 93 (91–95) | ||
| Nested PCR | 4 | 82 (46–96) | 92 (88–95) | 10.7 (5.9–19.4) | 0.19 (0.05–0.79) | 55 (9–339) | 93 (91–95) | ||
| Real-time PCR | 7 | 84 (71–92) | 100 (45–100) | 44.0 (5.7–335.4) | 0.16 (0.08,0.65) | 255 (40–607) | 93 (91–95) | ||
| LAMP PCR | 2 | 93 (88 –97) | 100 (98 –100) | 68.8 (0.68–925.8) | 0.07 (0.03–0.13) | ||||
| Commercial | Cobas Amplicor MTB | 4 | 48 (35–61) | 98 (97–99) | 25.3 (12.9–49.7) | 0.53 (0.41–0.68) | 48 (21–109) | 94 (91–95) | |
| GeneXpert | 16 | 61 (52–70) | 99 (97–99) | 42.0 (20.6–85.2) | 0.39 (0.31–0.50) | 107 (64–251) | 92 (89–94) | ||
| Gen-Probe MTD | 4 | 86 (52–97) | 99 (95–100) | 92.4 (14.8–577.6) | 0.15 (0.03–0.63) | 634 (31–1,299) | 99 (98–100) | ||
| CRS | In-house | Conventional PCR (IS6110 gene) | 9 | 87 (46–98) | 98 (88–100) | 39.2 (7.8–197.8) | 0.13 (0.02–0.78) | 119 (42–332) | 99 (97–99) |
| Conventional PCR (MPB64 gene) | 4 | 27 (02–85) | 99 (91–100) | 35.9 (1.7–751.1) | 0.74 (0.36–1.52) | 45 (8–249) | 99 (97–99) | ||
| Nested PCR | 3 | 80 (70 –88) | 95 (0.89–98) | 11.9 (5.3–6.7) | 0.23 (0.05–1.02) | 86 (7–1,049) | 97 (93–99) | ||
| Commercial | GeneXpert | 2 | 66 (38–88) | 89 (80–95) | 7.0 (3.8–12.8) | 0.23 (0.00–19.53) |
a
CRS, combined reference standard; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; LAMP, loop-mediated isothermal amplification.